Articles From: eSchool News Readers’ Choice Awards Name the Fast ForWord Program as One of the Top K-12 Ed-Tech Products for 2014-15 to ESPN's Stephen A. Smith to Host New National Radio Show Exclusively on SiriusXM; ESPN Radio to Produce the Daily Program


The Fast ForWord ® online reading intervention from Scientific Learning Corp.
Sign-up for eSchool News Readers’ Choice Awards Name the Fast ForWord Program as One of the Top K-12 Ed-Tech Products for 2014-15 investment picks
Diodes Incorporated (Nasdaq: DIOD), a leading global manufacturer and supplier of high-quality application specific standard products within the broad discrete, logic and analog semiconductor markets, today introduces an automotive-quality graded ESD and surge protector offering improved protection, greater reliability and easier inspection during manufacturing compared to Zener-based and varistor devices.
Sign-up for ESD and Surge Protector from Diodes Incorporated Offers Optimal Protection and Easy Inspection investment picks
ESH Hospitality, Inc., which along with Extended Stay America, Inc. (NYSE:STAY) (together, the “Company”) is an issuer of the Company’s Paired Shares, today announced that Lisa Palmer has been appointed to its Board of Directors as an independent director.
Sign-up for ESH Hospitality, Inc. Announces Appointment of Lisa Palmer to Board of Directors investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that Richard H.
Sign-up for ESI Adds New Board Member investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced results for its fiscal 2015 first quarter ended June 28, 2014.
Sign-up for ESI Announces First Quarter Fiscal 2015 Results investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), an innovator of laser-based manufacturing solutions for the microtechnology industry, today announced the µFlex TM Series multi-axis precision laser micromachining platform, enabling new levels of price-performance in laser applications for consumer electronics, medical devices, automotive components, and many other industries.
Sign-up for ESI Announces New Highly Versatile Laser Micromachining Platform investment picks
Electro Scientific Industries, Inc. (Nasdaq:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that its board of directors declared a quarterly cash dividend of $0.08 per share.
Sign-up for ESI Declares Quarterly Dividend investment picks
Electro Scientific Industries, Inc. (Nasdaq:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, will announce results for its fiscal 2015 first quarter after the market closes on Thursday, July 31, 2014.
Sign-up for ESI Schedules Fiscal 2015 First Quarter Earnings Conference Call for July 31 investment picks
Schubert Jonckheer & Kolbe LLP Investigates Case Against the Company's Top Executives SAN FRANCISCO , Sep.
Sign-up for ESI Shareholder Alert: Do You Own Stock in ITT Educational Services? investment picks
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, will host its 2014 Investor and Financial Analyst Conference in New York on October 1.
Sign-up for ESI to Host Investor and Analyst Conference in New York on October 1 investment picks
One of the Nation's Largest Safety Net Health Systems will Use the Market Leading Business Analytics Solutions to Measure, Predict, and Improve its Financial and Operational Performance ATLANTA , July 28, 2014 /PRNewswire/ --
Sign-up for Eskenazi Health Signs Agreement For Business Analytics And Patient Financial Solutions From Streamline Health® investment picks
WHIPPANY, N.J. , Sept.
Sign-up for ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise investment picks
Esperion Therapeutics Inc. (ESPR) reported favorable trial data for a cholesterol-reduction drug, pushing shares up sharply after hours.
Sign-up for Esperion Reports Favorable Cholesterol Drug Data investment picks
By Josh Beckerman Esperion Therapeutics Inc. (ESPR) reported favorable trial data for a cholesterol-reduction drug, pushing shares up sharply after hours.
Sign-up for Esperion Reports Favorable Cholesterol Drug Data -- Update investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Shares of Esperion Therapeutics Inc. rallied after the drug developer said its treatment significantly lowered bad cholesterol in patients enrolled in a clinical trial.
Sign-up for Esperion shares rally on cholesterol drug study investment picks
Esperion Therapeutics Inc. (ESPR) shares rallied in the extended session Wednesday after the drug developer said a mid-stage clinical trial showed its drug candidate significantly lowered bad cholesterol.
Sign-up for Esperion shares rally on cholesterol drug study results investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced dosing of the first patient in its Phase 2 clinical study of ETC-1002 in patients with hypercholesterolemia and hypertension, ETC-1002-014.
Sign-up for Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-008, a Phase 2b study evaluating the efficacy and safety of ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance.
Sign-up for Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia investment picks
Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014.
Sign-up for Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Second Quarter 2014 Financial Results investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host its inaugural analyst and investor day event and webcast for institutional investors and research analysts on Tuesday, July 29 at 8:30 a.m. Eastern Time.
Sign-up for Esperion Therapeutics to Host Inaugural Analyst and Investor Day investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the Company will present at the BioCentury NewsMakers in the Biotech Industry Conference in New York City, N.Y. The presentation will take place on Friday, September 26 at 8:30 a.m. Eastern Time, when Tim M.
Sign-up for Esperion Therapeutics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference investment picks
Esperion Therapeutics, Inc. (NASDAQ: ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results from the second quarter 2014.
Sign-up for Esperion Therapeutics to Provide Second Quarter 2014 Results investment picks
2014/8/13
Espial Highlights Advanced DVB and RDK User Experience at IBC Show Canada NewsWire Company demos HTML5 UX and RDK Application Framework for DVB set-top boxes OTTAWA , Aug.
Sign-up for Espial Highlights Advanced DVB and RDK User Experience at IBC Show investment picks
Espial Products Honored by BTR Technology Reviews Canada NewsWire Company's UX and RDK Application Framework receive 4.0 Diamond Technology Review Ranking OTTAWA , Sept.
Sign-up for Espial Products Honored by BTR Technology Reviews investment picks
Espial Showcases Advanced TV User Experience based on RDK at CableLabs® Summer Conference Canada NewsWire Company demos HTML5 UX and Application Framework on RDK-based set-top boxes OTTAWA , July 29, 2014 /CNW/ - Espial, a leader in on-demand TV software and solutions, today announced its participation at the upcoming 2014 CableLabs® Summer Conference taking place between August 3-6 in Keystone, Colo.
Sign-up for Espial Showcases Advanced TV User Experience based on RDK at CableLabs® Summer Conference investment picks
2014/7/18
By Patricia Kowsmann LISBON --
Sign-up for Espirito Santo International files for creditor protection investment picks
2014/8/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G020520-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/8/26/11G020520/esplanade-capital_logo-717340523798.jpg http://www.marketwire.com/library/MwGo/2014/8/26/11G020520/Images/ARHN_Press_Release_08.27.2014-345821058670.jpg Map of North Las Vegas Strip BOSTON, MA--(Marketwired - August 27, 2014) - Esplanade Capital LLC ("Esplanade" or "we"), the second largest outside shareholder (based on Bloomberg data) of Archon Corporation (PINKSHEETS: ARHN) ("Archon" or the "Company"), has raised its offer to acquire all outstanding shares of the Company to a price of $21.65 per share in a negotiated transaction, subject to confirmatory due diligence.
Sign-up for Esplanade Capital Raises Offer for Archon Corporation to $21.65 per Share investment picks
2014/7/24
ESPN, Time Warner Cable and Bright House Networks have reached an agreement for carriage of the SEC Network when the channel launches on August 14, 2014.
Sign-up for ESPN, Time Warner Cable and Bright House Networks Reach Agreement to Carry SEC Network for August 14, 2014 Debut investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: eSchool News Readers’ Choice Awards Name the Fast ForWord Program as One of the Top K-12 Ed-Tech Products for 2014-15 to ESPN's Stephen A. Smith to Host New National Radio Show Exclusively on SiriusXM; ESPN Radio to Produce the Daily Program
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices